nonalcoholic fatty liver disease
Conditions
Interventions
1:atorvastatin 40mg QD given orally
2:placebo QD given orally
Sponsors
the 1st Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: All patients had compensated liver diseasewith hemoglobin values of 12 g/dL or greater in females and13 g/dL or greater for males, a white blood cell countof >3000/mm3, neutrophil count >1500/mm3, platelets>70,000/mm3, albumin >3.0 g/dL, in addition to normaltotal bilirubin, prothrombin time, and Internationalnormalized ratio. Other requirements included serumcreatinine 200 mg/dL,LDL >130 mg/dL, or TGs >200 mg/dL.
Exclusion criteria
Exclusion criteria: Any other cause of chronic liver disease; history of alcohol consumption greater than 1 drink per day, prior surgical disease to include gastroplasty; jejuno-ileal or jejuno-colic bypass; prior exposure to organic solvents such as carbon tetrachloride; total parenteral nutrition within the previous 6 months, prior organ transplantation; prior treatment with a statin within the past 12 weeks, or use of tamoxifen, prednisone, chloroquine, methotrexate, highly active retroviral therapy, amiodarone, or any other hepatoxic medications. Additionally, patients with serum transaminases greater than or equal to 3 times the upper limit of normal were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver biopsy; | — |
Secondary
| Measure | Time frame |
|---|---|
| ultrasonographic exam of liver; | — |
Countries
China
Contacts
Public ContactXiang-Jun Yang
Outcome results
None listed